



**IN THE UNITED STATES  
PATENT AND TRADEMARK OFFICE**

APPLICANT: G. Scott Herron  
APPLICATION NO.: 09/905,704  
FILING DATE: February 27, 2001  
TITLE: In Vivo Assay For Anti-Angiogenic Compounds  
EXAMINER: Valerie E. Bertoglio  
GROUP ART UNIT: 1632  
ATTY. DKT. NO.: 23946-08185

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited on the date shown below with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Issue Fee, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 19/2004

By: Narinder S. Banait  
Narinder S. Banait, Ph.D., Reg. No.: 43,482

MAIL STOP ISSUE FEE  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**SUMMARY OF THE INTERVIEW**

SIR:

An interview was initiated by the Examiner on November 19, 2003. The Examiner faxed an Examiner's amendment to claims 1-30. On November 21, 2003, the entry of Examiner's amendment was authorized by the applicant.

A second interview was initiated by the Examiner on November 24, 2003. No claims were discussed. The priority claim contained a typographical error that was corrected. Further, an agreement was reached to remove the claim to priority from WO 00/56988.

A third interview was conducted on December 3, 2003. Claims 4, 5, 15, 18, 19,

27, and 30 were discussed. It was agreed to remove “stably transformed” and to further amend claim 27 to remove the phrase “in said host.”